دورية أكاديمية
أعرض في EDS

Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study.

التفاصيل البيبلوغرافية
العنوان: Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study.
المؤلفون: Miron AA; Transilvania University of Brasov, 56 Nicolae Bălcescu Str., 500019, Brasov, Romania., Teodorescu A; Transilvania University of Brasov, 56 Nicolae Bălcescu Str., 500019, Brasov, Romania. andre_martie@yahoo.com., Ifteni P; Transilvania University of Brasov, 56 Nicolae Bălcescu Str., 500019, Brasov, Romania., Irimie CA; Transilvania University of Brasov, 56 Nicolae Bălcescu Str., 500019, Brasov, Romania., Dima L; Transilvania University of Brasov, 56 Nicolae Bălcescu Str., 500019, Brasov, Romania., Petric PS; Transilvania University of Brasov, 56 Nicolae Bălcescu Str., 500019, Brasov, Romania.
المصدر: The Psychiatric quarterly [Psychiatr Q] 2022 Jun; Vol. 93 (2), pp. 627-635. Date of Electronic Publication: 2022 Mar 02.
نوع المنشور: Journal Article; Observational Study
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 0376465 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-6709 (Electronic) Linking ISSN: 00332720 NLM ISO Abbreviation: Psychiatr Q Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : New York, NY : Kluwer Academic/Plenum Publishers
Original Publication: Utica, N. Y.
مواضيع طبية MeSH: Antipsychotic Agents* , COVID-19*, Adult ; Delayed-Action Preparations ; Humans ; Olanzapine ; Pandemics
مستخلص: Schizophrenia is a psychiatric condition with chronic evolution, one of the most disabling diseases. The main cause for the disease's progression is considered to be the lack of compliance with the treatment. Long-acting injectable antipsychotics (LAIs) are an important treatment option for patients with schizophrenia. Olanzapine long-acting injection (OLZ-LAI) is a pamoate monohydrate salt of olanzapine that is administered by deep intramuscular gluteal injection. The aim of this paper is to report the effects of a sudden and unplanned switch from olanzapine long-acting injectable to oral olanzapine in remitted patients with schizophrenia due to restrictions caused by the COVID-19 pandemic. An observational study conducted in the Clinical Hospital of Psychiatry and Neurology of Brasov, Romania between April 2020 and March 2021. 27 patients with OLZ-LAI were entered into the study. Of 27 cases, 21 patients preferred to be switched to oral olanzapine (77.77%). Only 6 patients continued with the long-acting formulation. The main reason for the initiation of olanzapine pamoate in all the patients was non-adherence to oral medication (80.95%), and the mean age of starting LAI olanzapine was 36.42 years (SD ± 10.09). Within the following 12 months after switching from olanzapine LAI to OA, 15 patients (71.42%) relapsed, and 12 were admitted to the emergency psychiatric unit. The COVID-19 pandemic has brought multiple disservices to current medical practice. Sudden and unplanned switch from olanzapine long-acting formulation to oral olanzapine was followed by the high rate of relapse in remitted schizophrenia.
(© 2022. Springer Science+Business Media, LLC, part of Springer Nature.)
References: Kane JM. Review of treatments that can ameliorate non-adherence in patients with schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):9–14. (PMID: 16822091)
Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127:83–92. (PMID: 10.1016/j.schres.2010.11.020)
Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2–44. (PMID: 10.3109/15622975.2012.739708)
Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19(1):3–5. (PMID: 10.1017/S1092852913001016)
Detke HC, Zhao F, Witte MM. Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data. BMC Psychiatry. 2012;12:51. https://doi.org/10.1186/1471-244X-12-51 . (PMID: 10.1186/1471-244X-12-51226468473403915)
Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167:181–9. (PMID: 10.1176/appi.ajp.2009.07081221)
European Medicines Agency: Assessment report for Zypadhera. 2008, Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Zypadhera/H-890-en6.pdf . Accesed 28 May 2020.
Electronic Medicines Compendium: Summary of product characteristics for ZYPADHERA 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection. 2009. Available at: http://www.medicines.org.uk/emc/medicine/21361/S . Accesed 28 May 2020.
Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin. 2011;27(4):713–30. (PMID: 10.1185/03007995.2011.554533)
McDonnell DP, Landry J, Detke HC. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label stud. Int Clin Psychopharmacol. 2014;29(6):322–31. (PMID: 10.1097/YIC.0000000000000038)
Ifteni PI, Teodorescu A. Prevention of catatonia with olanzapine long-acting injectable. Am J Ther. 2017;24(5):e599–601. (PMID: 10.1097/MJT.0000000000000479)
Taylor DM, Velaga S, Werneke U. Reducing the stigma of long acting injectable antipsychotics - current concepts and future developments. Nord J Psychiatry 2018;72 (sup1): S36-S39.
Yeo PJI, Jang JM, et al. Acceptance rate of long-acting injection after short information: a survey in patients with first- and multiple-episode psychoses and their caregivers. Early Interv Psychiatry. 2017;11(6):509–16. (PMID: 10.1111/eip.12262)
Ifteni P, Dima L, Teodorescu A. Long-acting injectable antipsychotics treatment during COVID-19 pandemic - A new challenge. Schizophr Res. 2020;S0920–9964(20)30237–1. https://doi.org/10.1016/j.schres.2020.04.030 .
Gannon JM, Conlogue J, Sherwood R, et al. Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions. Schizophr Res. 2020;S0920–9964(20)30253-X. https://doi.org/10.1016/j.schres.2020.05.001 .
Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47–53. https://doi.org/10.4088/jcp.v69n0107 . (PMID: 10.4088/jcp.v69n010718312037)
Ascher-Svanum H. William S Montgomery, David P McDonnell, et al. treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. Int J Gen Med. 2012;5:391–8. (PMID: 10.2147/IJGM.S29052)
Citrome L. Long-acting injectable antipsychotics: what, when, and how. CNS Spectr. 2021;15:1–12. https://doi.org/10.1017/S1092852921000249 . (PMID: 10.1017/S1092852921000249)
Keks N, Schwartz D, Hope J. Stopping and switching antipsychotic drugs. Aust Prescr. 2019;42:152–7. (PMID: 10.18773/austprescr.2019.052)
فهرسة مساهمة: Keywords: Long-acting antipsychotic; Olanzapine pamoate; Relapse; Schizophrenia
المشرفين على المادة: 0 (Antipsychotic Agents)
0 (Delayed-Action Preparations)
N7U69T4SZR (Olanzapine)
تواريخ الأحداث: Date Created: 20220302 Date Completed: 20220429 Latest Revision: 20230119
رمز التحديث: 20230120
مُعرف محوري في PubMed: PMC8888267
DOI: 10.1007/s11126-021-09924-9
PMID: 35235126
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-6709
DOI:10.1007/s11126-021-09924-9